Navigation Links
Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
Date:12/20/2007

ROCKVILLE, Md., Dec. 20 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today favorable interim results from a Phase I/IIa human clinical trial of its non-adjuvanted pandemic influenza virus-like particle (VLP) vaccine candidate.

Penny Heaton, MD, Chief Medical Officer and Head of Clinical Development stated, "The initial results from our Phase I/IIa study are promising and support further development of our pandemic influenza vaccine through regulatory licensure. We are moving forward with a dose ranging study as anticipated. These data illustrate the potential of the VLP platform to provide well tolerated and effective vaccines against difficult viral targets, such as the H5N1 avian influenza strain."

In the initial stage of this study, seventy healthy adults 18 to 40 years of age received two doses of either 15 or 45 mcg of the H5N1 VLP vaccine candidate or a placebo. The goal was to evaluate safety and immunogenicity, including hemagglutinin inhibition (HAI) and neutralizating antibody responses.

The interim results indicate that the vaccine was well tolerated in all study groups. An independent Data and Safety Monitoring Board (DSMB) reviewed the safety data and recommended that Novavax proceed with the second stage of the study, in which the safety and immunogenicity of a range of doses up to 90 mcg will be evaluated.

The vaccine also induced good immune responses. Among those individuals in the 45 mcg arm (N=35), 83% had neutralizing antibody against the H5N1 A/Indonesia/05/2005 avian flu strain after the second vaccination. Sixty- three (63) percent had a 4-fold rise in neutralizing antibody from baseline. In regard to HAI responses, 48% had a 4-fold increase in titer from baseline. All
'/>"/>

SOURCE Novavax, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novavax CEO to Present at ACUMENBioFins 9th Annual Healthcare Conference
2. Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs
3. GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
4. Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... BETHESDA, Md. , Sept. 19, 2014 ... an initiative to harmonize global post-approval changes protocols. ... level of interest in the topic expressed by industry participants ... workshop, held earlier this month in Washington, ... and EMA were on hand for the workshop. Attendees ...
(Date:9/19/2014)... Sept. 19, 2014 Kiromic, LLC, a ... Kent Hance , the former chancellor of Texas Tech ... as chancellor in July 2014, after raising $1.2 billion for ... Kent Hance , the most successful chancellor in the ... not only as an investor, but also as our new ...
(Date:9/19/2014)... Research and Markets has announced the addition of ... Mental Disorder) Market - Forecast to 2023" report to ... the human microbiome market is segmented by application, disease, product, ... to be valued as $294 million in 2019 and is ... forecast period of 2019-2023. The market is driven by growing ...
Breaking Medicine Technology:PDA Launches Effort to Harmonize Global Post-Approval Changes Protocols 2Former Texas Tech Chancellor Named New Vice Chairman of the Board of Kiromic, LLC 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3
... ALISO VIEJO, Calif., Nov. 9 Clarient, Inc. (Nasdaq: ... oncologists and the pharmaceutical industry, today announced that it is ... New York City. , The first presentation will be made ... 1:40 pm EST on Tuesday, November 17. The conference will ...
... Care Reform Bill , Critical legislation would strengthen ... Nov. 7 Today the United States House ... strengthen Medicare for seniors and end discrimination by insurance companies ... , The Affordable Health Care for America Act ...
Cached Medicine Technology:Clarient to Present at Upcoming Healthcare Investor Conferences in New York City 2AARP Idaho Key Vote News Alert 2AARP Idaho Key Vote News Alert 3
(Date:9/19/2014)... structure could help predict how willing you are to take ... University found those with greater volume in a part of ... likely to engage in risky behavior than people with less ... the U.S. National Institute on Aging, involved two groups of ... researchers sought to determine how brain structure influences risk taking ...
(Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- Although ... key health benefits, most middle-aged and older adults ... type of exercise, according to new research. ... the muscle-strengthening recommendations set by the Department of ... Strength is essential for promoting health and ...
(Date:9/19/2014)... By Alan Mozes ... (HealthDay News) -- Cancer patients burdened by stress and ... for complications following their operation, a new study suggests. ... "deficit" appeared to have a nearly three times greater ... or good quality of life. "We,ve long known ...
(Date:9/19/2014)... York, NY (PRWEB) September 19, 2014 ... statin medication caused some patients to develop Type 2 ... litigation now underway in U.S. District Court, District of ... Status Report issued on September 12, 2014, discovery is ... things, the report noted that Pfizer, Inc., the manufacturer ...
(Date:9/19/2014)... using intact cells to treat and cure disease ... it is hindered by the inability of doctors and ... of these cells in patients without resorting to invasive ... September 17 in the online journal Magnetic Resonance ... San Diego School of Medicine, University of Pittsburgh and ...
Breaking Medicine News(10 mins):Health News:Brain Structure Might Help Predict Risky Behavior 2Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 3Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 3Health News:A better way to track emerging cell therapies using MRIs 2
... By Jenifer Goodwin HealthDay Reporter , THURSDAY, ... antigen (PSA) levels are rising rapidly over time are of ... be done, a new study indicates. PSA is a ... of PSA can be a marker for prostate cancer, although ...
... By Amanda Gardner HealthDay Reporter , THURSDAY, Feb. ... plague will probably remain a scourge of centuries past, isolated ... fact, according to a just-released government report, a American lab ... of plague from a laboratory-acquired infection since 1959 and the ...
... , THURSDAY, Feb. 24 (HealthDay News) -- ... risk of cancer due to high radiation doses, and ... radiation exposure, a new study suggests. The researchers ... dialysis also have other health conditions that require them ...
... cancer organizations have recommended that men with a rapid rise ... there is no other indication and the PSA is within ... PSA velocityis a poor predictor of prostate cancer, and may ... online February 24 in the Journal of the National ...
... link between victimization experiences and substance abuse has been ... Chicago. The correlation is especially prevalent among gays, ... says Tonda Hughes, professor and interim head of health ... is lead author of the study, published in the ...
... THURSDAY, Feb. 24 (HealthDay News) -- A mouse heart rapidly ... a day after birth, scientists report. With this discovery, ... be found to help the human heart heal itself. ... but they,re somehow permanently switched off," said Eric Olson, co-senior ...
Cached Medicine News:Health News:Rapid Rise in PSA Levels a Poor Predictor of Prostate Cancer: Study 2Health News:Rapid Rise in PSA Levels a Poor Predictor of Prostate Cancer: Study 3Health News:Plague Kills U.S. Lab Worker 2Health News:Plague Kills U.S. Lab Worker 3Health News:Many Dialysis Patients at Risk for High Radiation Exposure 2Health News:PSA velocity screening for prostate cancer may lead to unnecessary biopsies 2Health News:Strong link found between victimization, substance abuse 2Health News:Scientists Say Newborn Mice Can Regrow Damaged Hearts 2
Bio-Rad's ScanGel® cards for ABO reverse grouping, antibody screening and crossmatching include - ScanGel Neutral, ScanGel Coombs, Anti-IgG, -C3d (AHG), ScanGel Coombs + Neutral, ScanGel Anti-Ig...
... The Criterion Dodeca cell, a component of the ... up to 12 Criterion gels in a single ... x 8.7 cm) than the traditional mini gel. ... to give you the optimal combination of separation ...
... The PROTEAN Plus Dodeca cell accommodates ... the capacity of first-dimension runs in the ... in a convenient format. The PROTEAN Plus ... with its plate electrodes, allow consistent, high-resolution ...
... ElectroXpress gel electrophoresis system mirrors a 96-well ... screening of PCR products to take place ... source (96-well) plate. Loading can be carried out ... first time in the industry two sets ...
Medicine Products: